Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 260

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 260
---
 to be approved in circumstances where such approval could not otherwise be obtained. Purchases of shares by the persons described above would allow them to exert more influence over the approval of the proposals to be presented at the Special Meeting and would likely increase the chances that such proposals would be approved. As of the date of this proxy statement/prospectus, there have been no such discussions and no agreements to such effect have been entered into with any such investor or holder. APx will file a Current Report on Form 8 -Kto disclose any arrangements entered into or significant purchases made by any of the aforementioned persons that would affect the vote on the proposals to be voted on at the Special Meeting. Any such report will include descriptions of any arrangements entered into or significant purchases by any of the aforementioned persons. The existence of financial and personal interests of our directors and officers may result in conflicts of interest, including a conflict between what may be in the best interests of the Company and its shareholders and what may be best for a director’s personal interests when determining to recommend that shareholders vote for the proposals. See the sections entitled “ Risk Factors” and “ Security Ownership of Certain Beneficial Owners and Management” for more information and other risks. 120 The Business Combination The Background of the Business Combination The terms of the Business Combination are the result of negotiations between representatives of APx and OmnigenicsAI. The following is a brief description of the background of these negotiations and the resulting Business Combination. On December 9, 2021, APx closed its IPO of 17,250,000 APx Units, which included the exercise of the underwriters’ option to purchase an additional 2,250,000 APx Units at the initial offering price to cover over -allotments. Each APx Unit consists of one SPAC Class A Ordinary Share, par value $0.0001 per share, and one -halfof one redeemable warrant of APx, each whole APx Warrant entitling the holder thereof to purchase one SPAC Class A Ordinary Share at an exercise price of $11.50 per share. The APx Units were sold at a price of $10.00 per unit, generating gross proceeds to APx of $172,500,000. Substantially concurrently with the closing of the IPO, APx completed the private sale of an aggregate of 8,950,000 Private Placement Warrants to the Sponsor at a purchase price of $1.00 per Private Placement Warrant, generating gross proceeds to APx